Trial Profile
A Phase 2 study of AKCEA-ANGPTL3-LRx in patients with familial partial lipodystrophy
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2017
Price :
$35
*
At a glance
- Drugs Vupanorsen (Primary)
- Indications Lipodystrophy
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 17 Nov 2017 New trial record